Gene editing therapy for primary hyperoxaluria tipe I (University of Navarra)

N/A

Report date: 2025/09/05 14:00:01

Base Information

Drug NameGene editing therapy for primary hyperoxaluria tipe I (University of Navarra)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsHyperoxaluria

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Navarra

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Navarra

Inactive CompaniesN/A

Active IndicationsHyperoxaluria

Inactive IndicationsN/A

Other Information

ATC CodeN/A